Skip to main content

Advertisement

Table 2 Cox univariate and multivariate analysis of the relative risks for death and recurrent disease according to TATI serum levels.

From: Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients

  Relative risk for death in all patients (Overall survival) Relative risk for second cancer, recurrence or death to any cause in curatively treated patients (Disease free survival)
   Univariate Multivariate   Univariate Multivariate
  n* HR (95% CI) HR (95% CI) n HR (95% CI) HR (95% CI)
Age at operation
   Age <75 years 180 1.0 (ref) 1.0 (ref) 148 1.0 (ref) 1.0 (ref)
   Age ≥75 years 129 1.88(1.34-2.62) 2.23(1.55-3.23) 116 2.00(1.39-2.86) 1.94(1.30-2.87)
Gender
   Female 161 1.0 (ref) 1.0 (ref) 134 1.0 (ref) 1.0 (ref)
   Male 164 0.86(0.62-1.18) 0.82(0.58-1.16) 136 0.84(0.59-1.20) 0.82(0.57-1.19)
Disease stage
   Stage I 44 1.0 (ref) 1.0 (ref) 44 1.0 (ref) 1.0 (ref)
   Stage II 134 0.95(0.52-1.74) 1.07(0.57-2.01) 132 1.36(0.75-2.45) 1.47(0.79-2.70)
   Stage III 96 1.84(1.02-3.34) 1.94(1.04-3.65) 92 2.25(1.25-4.06) 2.27(1.21-4.24)
   Stage IV 47 7.62(4.11-14.16) 6.88(3.43-13.82) 0 N/A N/A
Differentiation grade
   High-moderate 251 1.0 (ref) 1.0 (ref) 215 1.0 (ref) 1.0 (ref)
   Poor 70 1.55(1.07-2.25) 1.38(0.92-2.07) 55 1.31(0.86-2.00) 1.31(0.85-2.02)
Vascular invasion
   No invasion 271 1.0 (ref) 1.0 (ref) 243 1.0 (ref) 1.0 (ref)
   Invasion 38 2.24(1.45-3.46) 1.29(0.80-2.08) 21 1.67(0.94-2.98) 1.52(0.83-2.78)
s-CEA
   < 2,67 μg/L 159 1.0 (ref) 1.0 (ref) 146 1.0 (ref) 1.0 (ref)
   ≥2,67 μg/L 165 2.05(1.47-2.87) 1.60(1.11-2.32) 124 1.56(1.10-2.23) 1.59(1.10-2.32)
s-TATI
   < 15,59 μg/L 159 1.0 (ref) 1.0 (ref) 165 1.0 (ref) 1.0 (ref)
   ≥15,59 μg/L 165 2.40(1.74-3.33) 1.78(1.25-2.53) 105 2.00(1.40-2.84) 1.51(1.03-2.22)
t-TATI
   ≤50% cells 233 1.0 (ref) 1.0 (ref) 196 1.0 (ref) 1.0 (ref)
   > 50% cells 65 1.40(0.96-2.05) 1.25(0.85-1.86) 58 1.67(1.12-2.49) 1.56(1.04-2.34)